Pilot Study for Patients With Poor Response to Deferasirox
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to understand the differences between people who have a good
response to deferasirox (exjade) compared to people who have a poor response to this
medication when used for transfusion-dependent iron overload.
The hypothesis is that patients with poor responses have physiologic barriers to deferasirox
that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or
genetic factors.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital